Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... May 26, 2023 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 Load more HOT NEWS Breaking News: Supreme Court Upholds the Affordable Care Act FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
